Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
Deciphera Pharmaceuticals (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.